Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share allocation event rather than general financial performance.
Material Changes
On February 18, 2011, the Administrators of the US Retirement Savings Plan notified the registrant of an increase in the notional allocation of Ordinary share ADRs. This adjustment followed a re-valuation of the cash element of the notional investment held within the Plan. The transaction occurred at a price of $39.15 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: February 18, 2011.
- Transaction Price: $39.15 per ADR.
- Involved Parties: Dr K Belmonte (4 shares), Mr W C Louv (8 shares), Dr M M Slaoui (17 shares), and Dr D Pulman (12 shares).
- Nature of Event: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.